ERBB2 and breast cancer: Thus, it is likely that a reduction in proliferation rate occurs mainly at the beginning of the treatment, as suggested also by a strong reduction in Ki67 positivity in tumor tissue of HER2-positive BC patients of a window of opportunity trial treated with one cycle of trastuzumab [50].